Dexamethasone Dose for COVID‐19 in a Large U.S. Hospital Network From April 2020 to May 2023

ABSTRACT Purpose While potential harm from high doses of systemic dexamethasone for clinical management of COVID‐19 is an important concern, little is known about real world dexamethasone dosing in patients hospitalized with COVID‐19 in the United States. Methods Descriptive study to assess dexamethasone daily dose in adults with COVID‐19 in a large US hospital network, overall and by respiratory support requirements, extracted using semi‐ structured nursing notes. Results Of 332 430 hospitalizations with a COVID‐19 diagnosis, 201 637 (60.7%) hospitalizations included dexamethasone administration. The mean age of recipients was 63 years, 53.0% were male, and 64.5% White. Median time from admission to dexamethasone administration was 0 day (interquartile range [IQR], 0–1 days) and median duration of use was 5 (IQR, 3–9) days. Almost 80% of hospitalizations received standard daily doses (≤ 6 mg daily), 12.7% moderately high daily doses (> 6– ≤ 10 mg daily), and 8.1% high (> 10– ≤ 20 mg daily) or very high daily dose (> 20 mg daily). Over 20% of COVID‐19 hospitalizations requiring no oxygen or simple oxygen received high doses of systemic dexamethasone. Conclusions Given the findings from the UK RECOVERY trial, and the general uncertainty around safety of higher dexamethasone doses in those requiring more intense respiratory support, standard daily dexamethasone doses of 6 mg or less for hospitalized COVID‐19 requiring supplemental oxygen are recommended.